Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 4/20 | 0.49 |
| ▸ | CES1 | P23141 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16728161 | 0.95 | CES2 (0.50) | MAPTCES2CES1LMNAMEN1 | |
| SCHEMBL16728116 | 0.91 | MAPT (0.51) | MAPTCES2CES1PTGS2LMNA | |
| SCHEMBL24158280 | 0.86 | MAPT (0.47) | MAPTPTGS2LMNAMEN1KMT2A | |
| SCHEMBL24451168 | 0.85 | SMN1; SMN2 (0.49) | MAPTPTGS2MEN1KMT2AALDH1A1 | |
| SCHEMBL30040031 | 0.84 | MAPT (0.50) | MAPTCES2CES1PTGS2LMNA | |
| SCHEMBL6524082 | 0.84 | MAPT (0.50) | MAPTCES2CES1PTGS2LMNA | |
| SCHEMBL6524085 | 0.84 | MAPT (0.50) | MAPTCES2CES1PTGS2LMNA | |
| SCHEMBL17451351 | 0.84 | PDPK1 (0.54) | MAPTALDH1A1NPC1 | |
| SCHEMBL17451350 | 0.84 | PDPK1 (0.54) | MAPTALDH1A1NPC1 | |
| SCHEMBL24451167 | 0.83 | LMNA (0.49) | MAPTPTGS2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371296-B2 | Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371296-B2 | Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators | ALLERGAN, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160137616-A1 | BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | ALLERGAN, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137616-A1 | BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | ALLERGAN, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2015073140-A1 | 1,3,4-ALKENYL OXADIAZOLE AMINO ACID DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | ALLERGAN, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137616-A1 | BICYCLIC 1,3,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS' MODULATORS | S1PR3, S1PR1, S1PR4 | MAPT 3562/4885CES2 2696/4885CES1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.